Portfolio concentration
As of March 31, 2026 · N-PORT
Holdings
86
Top-10 weight
27.82%
Effective holdings
?
The number of equal-weight positions that would produce this portfolio's concentration (1 ÷ Herfindahl index). A 500-stock fund dominated by a few mega-caps might have only ~100 effective holdings.
57
Crowding
?
The value-weighted average number of funds that also own this fund's positions. High = consensus/crowded picks; low = holdings few other funds own.
631.0
Holdings
As of March 31, 2026 · N-PORT| # | Security | Ticker | Shares | Value | % of fund |
|---|---|---|---|---|---|
| 1 | MODERNA INC | — | 2,024 | $102.82K | 4.54% |
| 2 | JOHNSON&JOHNSON | — | 292 | $71.38K | 3.15% |
| 3 | UNITED THERAPEUTICS CORP DEL | — | 107 | $63.45K | 2.80% |
| 4 | PFIZER INC | — | 2,208 | $62.00K | 2.74% |
| 5 | LILLY ELI and CO | — | 65 | $59.79K | 2.64% |
| 6 | STOKE THERAPEUTICS INC | — | 1,759 | $57.27K | 2.53% |
| 7 | NATERA INC | — | 286 | $57.20K | 2.53% |
| 8 | AMGEN INC | — | 151 | $53.13K | 2.35% |
| 9 | TWIST BIOSCIENCE CORP | — | 1,103 | $52.41K | 2.32% |
| 10 | ASTRAZENECA PLC | — | 262 | $51.67K | 2.28% |
| 11 | STRUCTURE THERAPEUTICS INC ADR | — | 1,034 | $49.84K | 2.20% |
| 12 | AMICUS THERAPEUTICS INC | — | 3,435 | $49.67K | 2.19% |
| 13 | BIONTECH SE ADR | — | 533 | $47.37K | 2.09% |
| 14 | IONIS PHARMACEUTICALS INC | — | 621 | $46.63K | 2.06% |
| 15 | GILEAD SCIENCES INC | — | 318 | $44.32K | 1.96% |
| 16 | CRISPR THERAPEUTICS AG | — | 891 | $42.38K | 1.87% |
| 17 | IMMUNOME INC | — | 1,928 | $42.17K | 1.86% |
| 18 | NOVOZYMES A S | NSISB | 711 | $41.93K | 1.85% |
| 19 | BEAM THERAPEUTICS INC | — | 1,726 | $41.13K | 1.82% |
| 20 | 10X GENOMICS INC | — | 1,900 | $40.34K | 1.78% |
| 21 | DARLING INGREDIENTS INC | — | 622 | $38.47K | 1.70% |
| 22 | Novartis AG (Registered) | NVSEF | 248 | $37.30K | 1.65% |
| 23 | ROIVANT SCIENCES LTD | — | 1,307 | $36.20K | 1.60% |
| 24 | KRYSTAL BIOTECH INC | — | 138 | $35.65K | 1.57% |
| 25 | AGIOS PHARMACEUTICALS INC | — | 1,048 | $35.45K | 1.57% |
| 26 | BUNGE GLOBAL SA | — | 274 | $34.85K | 1.54% |
| 27 | NOVO NORDISK-B | — | 945 | $33.64K | 1.49% |
| 28 | INTELLIA THERAPEUTICS INC | — | 2,622 | $33.61K | 1.48% |
| 29 | CORTEVA INC | — | 392 | $32.81K | 1.45% |
| 30 | ARROWHEAD PHARMACEUTICALS INC | — | 517 | $32.42K | 1.43% |
| 31 | VERTEX PHARMACEUTICALS INC | — | 69 | $30.81K | 1.36% |
| 32 | REGENXBIO INC | — | 3,572 | $29.93K | 1.32% |
| 33 | ARCELLX INC | — | 252 | $28.93K | 1.28% |
| 34 | ALLOGENE THERAPEUTICS INC | — | 11,574 | $28.24K | 1.25% |
| 35 | BRISTOL-MYERS SQUIBB CO | — | 447 | $27.11K | 1.20% |
| 36 | TAKEDA PHARMACEU | — | 742 | $26.42K | 1.17% |
| 37 | REGENERON PHARMACEUTICALS INC | — | 33 | $25.50K | 1.13% |
| 38 | GENMAB A/S -SP ADR DEPOSITARY RECEIPT | GMAB | 931 | $24.98K | 1.10% |
| 39 | VERBIO VEREINI | — | 449 | $23.69K | 1.05% |
| 40 | BIOMARIN PHARMACEUTICAL INC | — | 410 | $23.16K | 1.02% |
| 41 | Bayer Aktiengesellschaft | BAYN | 506 | $22.96K | 1.01% |
| 42 | ARGENX SE SPONSORED ADR | — | 29 | $21.18K | 0.94% |
| 43 | VIKING THERAPEUTICS INC | — | 636 | $20.70K | 0.91% |
| 44 | VERACYTE INC | — | 637 | $20.52K | 0.91% |
| 45 | EDITAS MEDICINE INC | — | 8,182 | $20.21K | 0.89% |
| 46 | DANAHER CORP | — | 106 | $20.10K | 0.89% |
| 47 | ARCTURUS THERAPEUTICS HOLDINGS INC | — | 2,494 | $19.25K | 0.85% |
| 48 | ABSCI CORP | — | 6,319 | $18.96K | 0.84% |
| 49 | IOVANCE BIOTHERAPEUTICS INC | — | 5,273 | $18.51K | 0.82% |
| 50 | TEMPUS AI INC-A | — | 390 | $17.64K | 0.78% |
1 / 2
Next ›
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.